Skip to main content
Fig. 1 | Trials

Fig. 1

From: Repurposing Probenecid for the Treatment of Heart Failure (Re-Prosper-HF): a study protocol for a randomized placebo-controlled clinical trial

Fig. 1

Central illustration: cAMP-dependent and -independent calcitropes. Summary figure demonstrating mechanism of action of current medical therapies for the treatment of heart failure with reduced ejection fraction. LTCC, L-type calcium channel; Ca2+, calcium; NA+, sodium; cAMP, cyclic adenosine monophate; PKA, protein kinase A; PDE, phosphodiesterase E; K+, potassium; TRPV2, transient receptor potential vanilloid 2; SERCA, sarcoendoplasmic reticulum calcium transport ATPase; RYR, ryanodine receptor

Back to article page

Trials

ISSN: 1745-6215